WASHINGTON, April 12, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that its 4.75% Series A Mandatory Convertible Preferred Stock (the “Preferred Stock”), will automatically convert into shares of the Company’s Common Stock on April 15, 2022 (the “Conversion Date”). The conversion rate for each share of Preferred Stock will be 6.6632 shares of the Company’s Common Stock. Cash will be paid in lieu of fractional shares of Common Stock.
As previously announced, on April 15, 2022 holders of record at the close of business on March 31, 2022 will separately receive a final quarterly cash dividend of $11.875 per share on the Preferred Stock.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher’s globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life’s Potential. For more information, please visit www.danaher.com.
View original content:https://www.prnewswire.com/news-releases/danaher-announces-conversion-date-for-series-a-mandatory-convertible-preferred-stock-301524269.html
SOURCE Danaher Corporation
Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by…
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…
BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…
PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…
STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…